Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease

US11873295B2 · kind B2 · utility

Assignee

• PETRA PHARMA CORPORATION · US

Inventors

• Erin Danielle ANDERSON · Boulder, US
• Sean Aronow · Boulder, US
• Nicholas Boyles · Hillsboro, US
• Surendra DAWADI · Chesterfield, US
• Eugene Richard Hickey · Danbury, US
• Thomas Combs IRVIN · Erie, US
• Edward A. Kesicki · Bothell, US
• Gabrielle R. Kolakowski · Boulder, US
• Jennifer Lynn KNIGHT · Jersey City, US
• Manoj KUMAR · Longmont, US
• Katelyn Frances LONG · Lafayette, US
• Christopher Mayne · Boulder, US
• Alfredo PICADO · Superior, US
• Gerit Maria POTOTSCHNIG · San Diego, US
• Michael Brian WELCH · Westminster, US
• Tien WIDJAJA · Lafayette, US
• Xiaohong Chen · Broomfield, US
• Nathan E. Wright · San Diego, US
• Hua Wang · Columbus, US

Key dates

• Filing date: May 2, 2022
• Grant date: Jan 16, 2024
• Expiry date: May 2, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.